BEIJING TONGSHI FUTURE NETWORK TECHNOLOGY CO., LTD – Trademark Portfolio
Entity Type: 99
BEIJING TONGSHI FUTURE NETWORK TECHNOLOGY CO., LTD holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include XPAUX and NORWILL. The owner is based in BEIJING.
ROOM S125, 1ST FLOOR, BUILDING 1, NO.9 KEYUAN ROAD, ECONOMIC DEVELOPMENT ZONE, DAXING DISTRICT
BEIJING , CN
Showing of trademarks Trademarks
Trademark Classifications
BEIJING TONGSHI FUTURE NETWORK TECHNOLOGY CO., LTD's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does BEIJING TONGSHI FUTURE NETWORK TECHNOLOGY CO., LTD have?
BEIJING TONGSHI FUTURE NETWORK TECHNOLOGY CO., LTD has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does BEIJING TONGSHI FUTURE NETWORK TECHNOLOGY CO., LTD file in?
BEIJING TONGSHI FUTURE NETWORK TECHNOLOGY CO., LTD files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are BEIJING TONGSHI FUTURE NETWORK TECHNOLOGY CO., LTD's most well-known trademarks?
BEIJING TONGSHI FUTURE NETWORK TECHNOLOGY CO., LTD's registered trademark portfolio includes well-known marks such as XPAUX and NORWILL. These are among 2 currently registered trademarks in the portfolio.
What is BEIJING TONGSHI FUTURE NETWORK TECHNOLOGY CO., LTD's trademark registration success rate?
BEIJING TONGSHI FUTURE NETWORK TECHNOLOGY CO., LTD has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.